Bacterial Sepsis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Bacterial Sepsis – Drugs In Development, 2024 report and make more profitable business decisions.
Infection caused by bacteria known as bacterial sepsis. Sepsis is an emergency condition when existing infections in the body are triggered or body’s extreme response to an infection. Sepsis can result in multi organ damage and septic shock. It is also referred to as blood poisoning and septicemia. Flu, chest pain, paleness or bluish grey coloration of skin, rashes, SOB, fever, change in pulse rate, confusion, extreme pain and discomfort are common symptoms. Triggered with lung infections pneumonia, catheter associated infections. Evaluated by CRP levels, CBP, Lactate levels, venous blood gases, MRI, CT scan are done. Antibiotics are primary line drugs for sepsis followed by corticosteroids, monoclonal antibodies, fluid transfusions in septic shock conditions.
The Bacterial Sepsis drugs in development market research report provide comprehensive information on the therapeutics under development for Bacterial Sepsis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bacterial Sepsis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Bacterial Sepsis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 13 molecules, with 11 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Bacterial Sepsis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Bacterial Sepsis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Bacterial Sepsis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Acepre LLCApoglyx AB
Brandenburg Antiinfektiva GmbH
Centers of Biomedical Research Network
Northern Therapeutics Inc
Ohio State University
Oryn Therapeutics
ProThera Biologics Inc
Pylum Biosciences Inc
Ra Pharmaceuticals Inc
Recce Pharmaceuticals Ltd
Therakind Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Bacterial Sepsis reports